Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.

about

Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.A concise review of BCL-2 inhibition in acute myeloid leukemia.

P2860

Q40138696-148280FB-195C-40DB-A660-76FCCF484669 Q47271349-B93BFAEC-4983-4C38-88B9-823EF732E8BC

P2860

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.

Item

http://www.wikidata.org/entity/Q40575708

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Karyotype plus NPM1 mutation s ...... duction consolidation therapy.

@en

type

Item

label

Karyotype plus NPM1 mutation s ...... duction consolidation therapy.

@en

prefLabel

Karyotype plus NPM1 mutation s ...... duction consolidation therapy.

@en

P1476

Karyotype plus NPM1 mutation s ...... duction consolidation therapy.

@en

P2093

Ansgar Weltermann

http://www.w3.org/2001/XMLSchema#string

Berthold Streubel

http://www.w3.org/2001/XMLSchema#string

Iris Pöll

http://www.w3.org/2001/XMLSchema#string

Michael Kundi

http://www.w3.org/2001/XMLSchema#string

Otto Zach

http://www.w3.org/2001/XMLSchema#string

Susanne Herndlhofer

http://www.w3.org/2001/XMLSchema#string

Ulrich Jaeger

http://www.w3.org/2001/XMLSchema#string

Wolfgang R Sperr

http://www.w3.org/2001/XMLSchema#string

P2860

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry.

P304

1239-1245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24560

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Valent

P Knoebl

P577

2016-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27643573

http://www.w3.org/2001/XMLSchema#string

P921

karyotype

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.

about

P2860

P2860

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921